The medicine, Lenmeldy (atidarsagene autotemcel), is a one-time infusion made from the patient’s hematopoietic stem cells and modified copies of the arylsulfatase A gene, the FDA said. The genetic disease, which is caused by an ARSA gene deficiency, manifests into the loss of motor and cognitive function, and early death.
In a trial, 37 children received Lenmeldy and experienced a significant reduction in the risk of severe motor impairment and death compared to untreated children.
At 5 years old, 71% of treated children could walk without assistance. All study participants who had pre-symptomatic late infantile MLD were alive at 6 years old, compared to 58% of children in the control group.
Before treatment, patients must undergo high-dose chemotherapy. The drug approval was given to Orchard Therapeutics.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
